Literature DB >> 22132894

Inhibition of CXCL10 release by monomeric C3bi and C4b.

Y Takeda1, K Kaneda, F Jimma, N Shiobara, M Hidaka, A R Saniabadi, I Wakabayashi.   

Abstract

Cellulose acetate (CA) beads are often used for leucocyte apheresis therapy against inflammatory bowel disease. In order to clarify the mechanism of the anti-inflammatory effects of CA, global analysis of the molecules generated in blood by the interaction with CA beads was performed in this study. An activated medium was collected from whole blood that had been preincubated with CA beads, and the effects of the CA-activated medium on leucocyte function were investigated. Fresh blood was stimulated with lipopolysaccharide (LPS) or interferon (IFN)-β in the presence of the activated medium, and levels of chemokines and cytokines, including CXCL10 (IFN-inducible protein-10), and phosphorylated STAT1 (signal transducer and activator of transcription 1), which is known to be essential for CXCL10 production in leucocytes, were measured. IFN-β- or LPS-induced CXCL10 production, expression of CXCL10 mRNA and phosphorylation of STAT1 were significantly reduced in the presence of the medium pretreated with CA beads compared with the control without the CA bead treatment. The factors inhibiting CXCL10 production were identified as the C3 and C4 fragments by mass spectrometry. The monomeric C3bi and C4b proteins were abundant in the medium pretreated with CA beads. Furthermore, purified C3bi and C4b were found to inhibit IFN-β-induced CXCL10 production and STAT1 phosphorylation. Thus, STAT1-mediated CXCL10 production induced by stimulation with LPS or IFN was potently inhibited by monomeric C3bi and C4b generated by the interaction of blood with CA beads. These mechanisms mediated by monomeric C3bi and C4b may be involved in the anti-inflammatory effects of CA.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22132894      PMCID: PMC3248096          DOI: 10.1111/j.1365-2249.2011.04490.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

Review 2.  STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.

Authors:  Krzysztof Sikorski; Anna Czerwoniec; Janusz M Bujnicki; Joanna Wesoly; Hans A R Bluyssen
Journal:  Cytokine Growth Factor Rev       Date:  2011-07-12       Impact factor: 7.638

3.  Cellulose acetate beads activate the complement system but inactivate the anaphylatoxins generated.

Authors:  Yuji Takeda; Masahiro Ohba; Masamichi Ueno; Abbi R Saniabadi; Ichiro Wakabayashi
Journal:  Artif Organs       Date:  2010-12       Impact factor: 3.094

4.  Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46.

Authors:  M Kurita-Taniguchi; A Fukui; K Hazeki; A Hirano; S Tsuji; M Matsumoto; M Watanabe; S Ueda; T Seya
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

5.  C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes.

Authors:  Deanna M Santer; Brian E Hall; Thaddeus C George; Stephanie Tangsombatvisit; Chih Long Liu; Peter D Arkwright; Keith B Elkon
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

Review 6.  Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus.

Authors:  Y L Wu; Y Yang; E K Chung; B Zhou; K J Kitzmiller; S L Savelli; H N Nagaraja; D J Birmingham; B P Tsao; B H Rovin; L A Hebert; C Y Yu
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

Review 7.  CXCL10 and autoimmune diseases.

Authors:  Eun Young Lee; Zang-Hee Lee; Yeong Wook Song
Journal:  Autoimmun Rev       Date:  2008-12-25       Impact factor: 9.754

8.  T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity.

Authors:  G Frisullo; V Nociti; R Iorio; A K Patanella; D Plantone; A Bianco; A Marti; G Cammarota; P A Tonali; A P Batocchi
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

9.  Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.

Authors:  Matin M Imanguli; William D Swaim; Stacy C League; Ronald E Gress; Steven Z Pavletic; Frances T Hakim
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

10.  Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells.

Authors:  John Cardone; Gaelle Le Friec; Pierre Vantourout; Andrew Roberts; Anja Fuchs; Ian Jackson; Tesha Suddason; Graham Lord; John P Atkinson; Andrew Cope; Adrian Hayday; Claudia Kemper
Journal:  Nat Immunol       Date:  2010-08-08       Impact factor: 25.606

View more
  1 in total

1.  Suppression of Th1 cytokine production by a peptide derived from C4b.

Authors:  Yuji Takeda; Kenta Kaneda; Fumie Jimma; Noriyuki Shiobara; Abbi R Saniabadi; Ichiro Wakabayashi
Journal:  Inflamm Res       Date:  2013-08-25       Impact factor: 4.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.